R Barroso-Sousa1, W T Barry2, H Guo2, D Dillon3, Y B Tan3, K Fuhrman4, W Osmani1, A Getz3, M Baltay3, C Dang5, D Yardley6, B Moy7, P K Marcom8, E A Mittendorf9, I E Krop1, E P Winer1, S M Tolaney10. 1. Departments of Medical Oncology. 2. Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston. 3. Department of Pathology, Brigham and Women's Hospital, Boston. 4. Nanostring, Seattle. 5. Breast Cancer Medicine Service, Department of Medicine, Solid Tumor Division, Memorial Sloan Kettering Cancer Center, New York; Department of Medicine, Weill Cornell Medical Center, New York. 6. Tennessee Oncology, Nashville. 7. Department of Hematology-Oncology, Massachusetts General Hospital, Boston. 8. Department of Medicine, Division of Medical Oncology, Duke Cancer Institute, Durham. 9. Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, USA. 10. Departments of Medical Oncology. Electronic address: sara_tolaney@dfci.harvard.edu.
Abstract
BACKGROUND: Previous data suggest that the immune microenvironment plays a critical role in human epidermal growth factor receptor 2 (HER2) -positive breast cancer; however, there is little known about the immune profiles of small HER2-positive tumors. In this study, we aimed to characterize the immune microenvironment of small HER2-positive breast cancers included in the Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer (APT) trial and to correlate the immune markers with pathological and molecular tumor characteristics. PATIENTS AND METHODS: The APT trial was a multicenter, single-arm, phase II study of paclitaxel and trastuzumab in patients with node-negative HER2-positive breast cancer. The study included 406 patients with HER2-positive, node-negative breast cancer, measuring up to 3 cm. Exploratory analysis of tumor infiltrating lymphocytes (TIL), programmed death-ligand 1 (PD-L1) expression (by immunohistochemistry), and immune gene signatures using data generated by nCounter PanCancer Pathways Panel (NanoString Technologies, Seattle, WA), and their association with pathological and molecular characteristics was carried out. RESULTS: Of the 406 patients, 328 (81%) had at least one immune assay carried out: 284 cases were evaluated for TIL, 266 for PD-L1, and 213 for immune gene signatures. High TIL (≥60%) were seen with greater frequency in hormone-receptor (HR) negative, histological grades 2 and 3, as well in HER2-enriched and basal-like tumors. Lower stromal PD-L1 (≤1%) expression was seen with greater frequency in HR-positive, histological grade 1, and in luminal tumors. Both TIL and stromal PD-L1 were positively correlated with 10 immune cell signatures, including Th1 and B cell signatures. Luminal B tumors were negatively correlated with those signatures. Significant correlation was seen among these immune markers; however, the magnitude of correlation did not indicate a monotonic relationship between them. CONCLUSION: Immune profiles of small HER2-positive breast cancers differ according to HR status, histological grade, and molecular subtype. Further work is needed to explore the implication of these findings on disease outcome. CLINICAL TRIAL REGISTRATION: clinicaltrials.gov identifier: NCT00542451.
BACKGROUND: Previous data suggest that the immune microenvironment plays a critical role in humanepidermal growth factor receptor 2 (HER2) -positive breast cancer; however, there is little known about the immune profiles of small HER2-positive tumors. In this study, we aimed to characterize the immune microenvironment of small HER2-positive breast cancers included in the Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer (APT) trial and to correlate the immune markers with pathological and molecular tumor characteristics. PATIENTS AND METHODS: The APT trial was a multicenter, single-arm, phase II study of paclitaxel and trastuzumab in patients with node-negative HER2-positive breast cancer. The study included 406 patients with HER2-positive, node-negative breast cancer, measuring up to 3 cm. Exploratory analysis of tumor infiltrating lymphocytes (TIL), programmed death-ligand 1 (PD-L1) expression (by immunohistochemistry), and immune gene signatures using data generated by nCounter PanCancer Pathways Panel (NanoString Technologies, Seattle, WA), and their association with pathological and molecular characteristics was carried out. RESULTS: Of the 406 patients, 328 (81%) had at least one immune assay carried out: 284 cases were evaluated for TIL, 266 for PD-L1, and 213 for immune gene signatures. High TIL (≥60%) were seen with greater frequency in hormone-receptor (HR) negative, histological grades 2 and 3, as well in HER2-enriched and basal-like tumors. Lower stromal PD-L1 (≤1%) expression was seen with greater frequency in HR-positive, histological grade 1, and in luminal tumors. Both TIL and stromal PD-L1 were positively correlated with 10 immune cell signatures, including Th1 and B cell signatures. Luminal B tumors were negatively correlated with those signatures. Significant correlation was seen among these immune markers; however, the magnitude of correlation did not indicate a monotonic relationship between them. CONCLUSION: Immune profiles of small HER2-positive breast cancers differ according to HR status, histological grade, and molecular subtype. Further work is needed to explore the implication of these findings on disease outcome. CLINICAL TRIAL REGISTRATION: clinicaltrials.gov identifier: NCT00542451.
Authors: R Salgado; C Denkert; S Demaria; N Sirtaine; F Klauschen; G Pruneri; S Wienert; G Van den Eynden; F L Baehner; F Penault-Llorca; E A Perez; E A Thompson; W F Symmans; A L Richardson; J Brock; C Criscitiello; H Bailey; M Ignatiadis; G Floris; J Sparano; Z Kos; T Nielsen; D L Rimm; K H Allison; J S Reis-Filho; S Loibl; C Sotiriou; G Viale; S Badve; S Adams; K Willard-Gallo; S Loi Journal: Ann Oncol Date: 2014-09-11 Impact factor: 32.976
Authors: S Loi; S Michiels; R Salgado; N Sirtaine; V Jose; D Fumagalli; P-L Kellokumpu-Lehtinen; P Bono; V Kataja; C Desmedt; M J Piccart; S Loibl; C Denkert; M J Smyth; H Joensuu; C Sotiriou Journal: Ann Oncol Date: 2014-03-07 Impact factor: 32.976
Authors: Carsten Denkert; Gunter von Minckwitz; Silvia Darb-Esfahani; Bianca Lederer; Barbara I Heppner; Karsten E Weber; Jan Budczies; Jens Huober; Frederick Klauschen; Jenny Furlanetto; Wolfgang D Schmitt; Jens-Uwe Blohmer; Thomas Karn; Berit M Pfitzner; Sherko Kümmel; Knut Engels; Andreas Schneeweiss; Arndt Hartmann; Aurelia Noske; Peter A Fasching; Christian Jackisch; Marion van Mackelenbergh; Peter Sinn; Christian Schem; Claus Hanusch; Michael Untch; Sibylle Loibl Journal: Lancet Oncol Date: 2017-12-07 Impact factor: 41.316
Authors: Yanchun Li; Mateusz Opyrchal; Song Yao; Xuan Peng; Li Yan; Hossam Jabbour; Thaer Khoury Journal: Breast Cancer Res Treat Date: 2018-03-09 Impact factor: 4.872
Authors: P Nuciforo; T Pascual; J Cortés; A Llombart-Cussac; R Fasani; L Paré; M Oliveira; P Galvan; N Martínez; B Bermejo; M Vidal; S Pernas; R López; M Muñoz; I Garau; L Manso; J Alarcón; E Martínez; V Rodrik-Outmezguine; J C Brase; P Villagrasa; A Prat; E Holgado Journal: Ann Oncol Date: 2018-01-01 Impact factor: 32.976
Authors: SaeGwang Park; Zhujun Jiang; Eric D Mortenson; Liufu Deng; Olga Radkevich-Brown; Xuanming Yang; Husain Sattar; Yang Wang; Nicholas K Brown; Mark Greene; Yang Liu; Jie Tang; Shengdian Wang; Yang-Xin Fu Journal: Cancer Cell Date: 2010-08-09 Impact factor: 31.743
Authors: Joel S Parker; Michael Mullins; Maggie C U Cheang; Samuel Leung; David Voduc; Tammi Vickery; Sherri Davies; Christiane Fauron; Xiaping He; Zhiyuan Hu; John F Quackenbush; Inge J Stijleman; Juan Palazzo; J S Marron; Andrew B Nobel; Elaine Mardis; Torsten O Nielsen; Matthew J Ellis; Charles M Perou; Philip S Bernard Journal: J Clin Oncol Date: 2009-02-09 Impact factor: 44.544
Authors: Ahrong Kim; So Jeong Lee; Young Keum Kim; Won Young Park; Do Youn Park; Jee Yeon Kim; Chang Hun Lee; Gyungyub Gong; Gi Yeong Huh; Kyung Un Choi Journal: Sci Rep Date: 2017-09-15 Impact factor: 4.379
Authors: Aranzazu Fernandez-Martinez; Ian E Krop; David W Hillman; Mei-Yin Polley; Joel S Parker; Lucas Huebner; Katherine A Hoadley; Jonathan Shepherd; Sara Tolaney; N Lynn Henry; Chau Dang; Lyndsay Harris; Donald Berry; Olwen Hahn; Clifford Hudis; Eric Winer; Ann Partridge; Charles M Perou; Lisa A Carey Journal: J Clin Oncol Date: 2020-10-23 Impact factor: 44.544